World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
116
Citations
86714
World Ranking
4252
National Ranking
415

Overview

Thomas Powles is affiliated with Queen Mary University of London in the United Kingdom. Their research primarily focuses on renal cell carcinoma and cancer immunotherapy, with significant contributions to treatment approaches and biomarker development.

Their recent publications include:

  • Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial, 2020, The Lancet Oncology
  • European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update, 2022, European Urology

Thomas Powles has collaborated frequently with several coauthors throughout their career. These include:

  • Toni K. Choueiri
  • Robert J. Motzer
  • Brian I. Rini
  • Laurence Albigès
  • Camillo Porta

The scientist has published articles extensively in a number of venues. Notable frequent venues are:

  • Journal of Clinical Oncology
  • European Urology
  • The Oncologist
  • European Urology Oncology
  • The Lancet Oncology

Their work spans several main fields of study, predominantly:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these, significant subfields of study include:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Molecular Biology
  • Surgery
  • Cancer Research

The main research topics addressed by Thomas Powles are:

  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Renal and related cancers
  • Cancer Genomics and Diagnostics
  • Bladder and Urothelial Cancer Treatments
  • Economic and Financial Impacts of Cancer
  • Pancreatic and Hepatic Oncology Research

Best Publications

  • TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

    Sanjeev Mariathasan;Shannon J. Turley;Dorothee Nickles;Alessandra Castiglioni

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    Jonathan E Rosenberg;Jean Hoffman-Censits;Tom Powles;Michiel S van der Heijden

  • Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Brian I. Rini;Elizabeth R. Plimack;Viktor Stus;Rustem Gafanov

  • EAU Guidelines on Renal Cell Carcinoma: 2014 Update

    Borje Ljungberg;Karim Bensalah;Steven Canfield;Saeed Dabestani

  • MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    Thomas Powles;Joseph Paul Eder;Gregg D. Fine;Fadi S. Braiteh

  • Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

    Arjun V. Balar;Matthew D. Galsky;Jonathan E. Rosenberg;Thomas Powles

  • Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

    Thomas Powles;Ignacio Durán;Michiel S van der Heijden;Yohann Loriot

  • First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

    Arjun V Balar;Daniel Castellano;Peter H O'Donnell;Petros Grivas

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

    Robert Motzer;Boris Alekseev;Sun Young Rha;Camillo Porta

  • Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

    Toni K. Choueiri;Thomas Powles;Mauricio Burotto;Bernard Escudier

  • Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

    Toni K. Choueiri;Bernard Escudier;Thomas Powles;Paul N. Mainwaring

  • Overview of the main outcomes in breast-cancer prevention trials.

    J Cuzick;T Powles;U Veronesi;J Forbes

  • European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.

    Börje Ljungberg;Laurance Albiges;Yasmin Abu-Ghanem;Karim Bensalah

  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Brian I Rini;Thomas Powles;Michael B Atkins;Bernard Escudier

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.

    Lennard Y.W. Lee;Jean Baptiste Cazier;Vasileios Angelis;Roland Arnold

  • Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

    Thomas Powles;Se Hoon Park;Eric Voog;Claudia Caserta

  • A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

    Aurélie Kamoun;Aurélien de Reyniès;Yves Allory;Yves Allory;Gottfrid Sjödahl

  • Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Toni K Choueiri;Bernard Escudier;Thomas Powles;Nizar M Tannir

Frequent Co-Authors

Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center
Toni K. Choueiri
Toni K. Choueiri Harvard University
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Jonathan E. Rosenberg
Jonathan E. Rosenberg Memorial Sloan Kettering Cancer Center
Mark Bower
Mark Bower Imperial College London
Cora N. Sternberg
Cora N. Sternberg Cornell University
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Yohann Loriot
Yohann Loriot University of Paris-Saclay
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in the broader world of healthcare, online degrees create flexible opportunities to build rewarding careers beyond traditional medicine. Programs like the best online food science degree open pathways to roles in nutrition, wellness, and research—fields critical to public health.

Aspiring healthcare leaders can advance quickly with the best mha programs, which combine business management and healthcare expertise, suiting those looking to shape hospital policy or lead healthcare organizations.

Nursing professionals seeking higher qualifications now have options like rn to bsn programs without clinicals. These programs are ideal for working RNs who want to earn their bachelor’s degree online while balancing workplace commitments.

For experienced nurses aiming for the pinnacle of nursing education, accelerated msn to dnp programs offer fast-tracked advancement to the doctoral level, opening doors to teaching, leadership, and specialized clinical roles.

Exploring these online programs can help tailor a unique career path in the essential and rapidly-evolving healthcare landscape.

Best Scientists Citing Thomas Powles

Trending Scientists

Recently Published Articles